News
Chiltern Announces Expansion of Clinical Development Services in Endocrinology and Metabolism
(London, U.K., and Wilmington, N.C.; October 1, 2015) — Chiltern, a leading global contract research organization (CRO), is expanding its clinical development services in endocrinology and metabolism and has named Randy L. Anderson, Ph.D., as senior vice president of scientific affairs.
With nearly 30 years of industry experience, Anderson is an expert in diabetes and other endocrine/metabolism disorders. A board director for JDRF International, he also serves on multiple scientific advisory boards for pharmaceutical companies with endocrine products. He joins Chiltern after 18 years with another major clinical research organization, where he provided scientific leadership for the endocrinology and metabolism therapeutic area and was a key contributor on hundreds of trials and products. In addition to being the therapeutic area leader for endocrinology and metabolism, Anderson will serve as Chiltern’s administrative leader for its other scientific affairs experts across all therapeutic areas.
“Diseases of endocrinology and metabolism impose a daunting societal burden in terms of their morbidity and mortality,” Anderson said. “I am honored to join my experience with the entrepreneurial energy at Chiltern, to help our clients develop better treatments with speed, efficiency and robust scientific integrity.”
The endocrinology and metabolism area at Chiltern includes diseases of the endocrine organs and related complications: type 1 diabetes, type 2 diabetes, diabetes complications, obesity, dyslipidaemias, adrenal disorders, thyroid disorders, pituitary disorders, calcium homeostasis disorders, cardiovascular disease prevention, growth disorders, sex androgen dysfunction and other rare metabolic disease indications such as lysosomal storage disorders, Prader-Willi Syndrome and Fabry disease.
“Expanding our clinical development services for endocrinology and metabolism diseases is a direct response to client desire for collaborative partnerships in development planning, design and execution of clinical trials in this complex therapeutic area,” said Dr. Jim Esinhart, Chiltern CEO. We are excited to add Dr. Anderson’s energy and leadership to our offerings in the endocrinology and metabolism therapeutic area.”
About Chiltern:
Chiltern is the leading, global mid-sized contract research organization that listens to client needs to deliver customized clinical development solutions. Chiltern’s team of more than 3,700 works across 47 countries to provide flexible, specialized services, with core competencies in Biopharma, Medical Device and Diagnostics, Oncology, Clinical Analytics and Source. Visit Chiltern.com to learn more about responsive solutions that are Designed Around You®.
Further information is available at: http://www.Chiltern.com/.